Skip to content

The effect of insulin detemir on energy balance, postprandial nutrient handling, body fat distribution,and adipose tissue metabolism and gene expression in patients with type 2 diabetes. - Metabolic Effects of Detemir

The effect of insulin detemir on energy balance, postprandial nutrient handling, body fat distribution,and adipose tissue metabolism and gene expression in patients with type 2 diabetes. - Metabolic Effects of Detemir

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-003085-17-GB
Enrollment
30
Registered
2007-11-26
Start date
2007-12-13
Completion date
Unknown
Last updated
2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus MedDRA version: 9.1 Level: LLT Classification code 10053247 Term: Insulin-requiring type 2 diabetes mellitus

Interventions

Trade Name: Levemir Pharmaceutical Form: Solution for injection Trade Name: Insulatard Pharmaceutical Form: Suspension for injection T

Sponsors

University of Surrey
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Informed consent 2. Type 2 diabetes mellitus 3. Treated with metformin 4. Already on treatment with twice-daily NPH insulin with or without short-acting insulin or a 'basal-bolus' regimen 5. Above 18 years of age 6. BMI 27-35 7. Able and willing to perform own blood glucose monitoring 8. Able and willing to maintain consistent eating habits throughout the entire study period 9. Able and willing to maintain consistent physical activity throughout the entire study period. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. Patients on sulphonylureas or thiazolidinediones 2. Proliferative retinopathy that has required acute treatment in the last 6 months 3. Impaired hepatic or renal function 4. Cardiac problems 5. Uncontrolled hypertension 6. Mental incapacity, unwillingness or a language barrier precluding adequate understanding or co-operation 7. Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures.

Design outcomes

Primary

MeasureTime frame
Main Objective: To compare the effects of treatment with insulin detemir for 16 weeks with the effects of treatment with NPH insulin for 16 weeks on energy expenditure.; Secondary Objective: To compare the above 2 treatments in terms of outcome with respect to: body weight waist-hip ratio achieved glycaemic control ;Primary end point(s): Energy expenditure after the 24-week treatment period.

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026